Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Free Report) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 450,100 shares, a growth of 20.3% from the November 15th total of 374,100 shares. Based on an average daily trading volume, of 144,200 shares, the short-interest ratio is presently 3.1 days.
Harvard Bioscience Stock Down 3.6 %
NASDAQ HBIO opened at $2.16 on Monday. The stock has a market capitalization of $94.22 million, a P/E ratio of -6.55 and a beta of 1.27. Harvard Bioscience has a 52 week low of $1.99 and a 52 week high of $5.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. The stock has a fifty day moving average of $2.33 and a 200-day moving average of $2.71.
Institutional Trading of Harvard Bioscience
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HBIO. Assenagon Asset Management S.A. boosted its stake in shares of Harvard Bioscience by 193.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after purchasing an additional 150,218 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Harvard Bioscience by 13.0% in the second quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock valued at $783,000 after acquiring an additional 31,505 shares during the last quarter. Vanguard Group Inc. grew its holdings in Harvard Bioscience by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after acquiring an additional 49,576 shares during the period. Renaissance Technologies LLC raised its position in shares of Harvard Bioscience by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after acquiring an additional 42,800 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Harvard Bioscience by 24.9% in the 2nd quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock valued at $136,000 after purchasing an additional 9,512 shares during the period. 80.87% of the stock is currently owned by institutional investors and hedge funds.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Further Reading
- Five stocks we like better than Harvard Bioscience
- How to Capture the Benefits of Dividend Increases
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- How to Use Stock Screeners to Find Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Why Are Stock Sectors Important to Successful Investing?
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.